Working...
ClinicalTrials.gov
ClinicalTrials.gov Menu
Trial record 16 of 75 for:    "Rabies" | "Immunologic Factors"

Immunity Duration of Rabies Vaccine and Booster Dose Effects at 10 Years Post-primary Vaccination

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
ClinicalTrials.gov Identifier: NCT03774628
Recruitment Status : Active, not recruiting
First Posted : December 13, 2018
Last Update Posted : December 13, 2018
Sponsor:
Information provided by (Responsible Party):
Jiangsu Province Centers for Disease Control and Prevention

Brief Summary:

A rabies vaccine (human diploid cell) for human use, Freeze-dried produced by Chengdu Kanghua Biological Products Co.,Ltd is used to prevent human rabies. The vaccine was completed in the Phase III clinical trial from August 2008 to February 2009 in Lianshui County, Jiangsu Province (Approval of Drug Clinical Trial No. 2008L03156). A total of 1200 subjects aged 10-60 years were randomly assigned trial group (Kanghua vaccine group, 600 participants) and control groups (Pasteur vaccine group, 600 participants). The result showed that this vaccine could provide good immunogenicity and mild adverse reactions. On April 28, 2012, the drug registration approval was obtained (Approval No. 2012S00222).

To disclose the effects of booster immunization of human diploid cell rabies vaccine (HDCV) after eight years of primary vaccination. Sixty subjects who had participated the phase Ⅲ clinical trial of freeze-dried HDCV were selected and given booster immunization after eight years of primary vaccination. The result showed that the freeze-dried HDCV has good immune effects with one-dose of booster immunization after eight years of primary vaccination. In order to find a ten years of immunization persistence and booster dose immune effect, the investigators decided to perform this immunization persistence and booster immunity trial among these subjects who had received five doses of rabies vaccine vaccines (around ten years after the fundamental immunity). The investigators do the recruitment among these subjects who had participated in the previous phase Ⅲ trail and the subjects were divided into two layers, such as trial group (Kanghua vaccine group) and the control group (Paste vaccine group). Each layer of the subjects randomly received one booster dose (Day 0) and two booster doses (Day 0, 3) the freeze-dried HDCV in a ratio of 1:1.


Condition or disease Intervention/treatment Phase
Rabies Biological: Chengdu Kanghua (one booster shot) Biological: Chengdu Kanghua (two booster shots) Not Applicable

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Estimated Enrollment : 342 participants
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: None (Open Label)
Primary Purpose: Prevention
Official Title: Long-term Immunity of Rabies Vaccine(Human Diploid Cell)for Human Use,Freeze-dried and Booster Dose Effects at 10 Years Post-primary Vaccination
Actual Study Start Date : August 1, 2018
Estimated Primary Completion Date : February 19, 2019
Estimated Study Completion Date : February 19, 2019

Resource links provided by the National Library of Medicine

MedlinePlus related topics: Rabies

Arm Intervention/treatment
Experimental: Chengdu Kanghua (one booster shot)
one dose, A rabies vaccine (human diploid cell) for human use, Freeze-dried produced by Chengdu Kanghua Biological Products Co.,Ltd.
Biological: Chengdu Kanghua (one booster shot)
A rabies vaccine (human diploid cell) for human use, Freeze-dried produced by Chengdu Kanghua Biological Products Co.,Ltd. 1.0 ml experimental vaccine on day 0

Experimental: Chengdu Kanghua (two booster shots)
two doses at 0 and 3 days, on A rabies vaccine (human diploid cell) for human use, Freeze-dried produced by Chengdu Kanghua Biological Products Co.,Ltd.
Biological: Chengdu Kanghua (two booster shots)
A rabies vaccine (human diploid cell) for human use, Freeze-dried produced by Chengdu Kanghua Biological Products Co.,Ltd. 1.0 ml experimental vaccine on day 0 and 3




Primary Outcome Measures :
  1. Proportion of serum rabies virus neutralizing antibodies to protective levels 10 years after primary vaccination [ Time Frame: 10 years after primary vaccination ]
    calculate the proportion of serum rabies virus neutralizing antibodies to protective levels 10 years after primary vaccination

  2. Geometric mean concentration (GMC) of serum rabies virus neutralizing antibody 10 years after primary vaccination [ Time Frame: 10 years after primary vaccination ]
    calculate the geometric mean concentration (GMC) of serum rabies virus neutralizing antibody 10 years after primary vaccination

  3. Proportion of serum rabies virus neutralizing antibodies to protective levels [ Time Frame: 6 hours, 1 day, 3 days, 7 days or 14 days after booster dose injection within 10 years later ]
    calculate the proportion of serum rabies virus neutralizing antibodies to protective levels 6 hours, 1 day, 3 days, 7 days or 14 days after booster dose injection within 10 years later

  4. Positive seroconversion rate of serum rabies virus neutralizing antibody [ Time Frame: 6 hours, 1 day, 3 days, 7 days or 14 days after booster dose injection within 10 years later ]
    calculate the positive seroconversion rate of serum rabies virus neutralizing antibody 6 hours, 1 day, 3 days, 7 days or 14 days after booster dose injection within 10 years later

  5. Geometric mean concentration (GMC) of serum rabies virus neutralizing antibody [ Time Frame: 6 hours, 1 day, 3 days, 7 days or 14 days after booster dose injection within 10 years later ]
    calculate the geometric mean concentration (GMC) of serum rabies virus neutralizing antibody 6 hours, 1 day, 3 days, 7 days or 14 days after booster dose injection within 10 years later

  6. Mean geometric increases (GMIs) of serum rabies virus neutralizing antibody [ Time Frame: 6 hours, 1 day, 3 days, 7 days or 14 days after booster dose injection within 10 years later ]
    calculate the mean geometric increases (GMIs) of serum rabies virus neutralizing antibody 6 hours, 1 day, 3 days, 7 days or 14 days after booster dose injection within 10 years later



Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Layout table for eligibility information
Ages Eligible for Study:   20 Years to 70 Years   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   Yes
Criteria

Inclusion Criteria:

  • Participants who participated in the Phase III clinical study of the vaccine and completed the full immunization
  • Subjects or legal guardians can and will comply with the requirements of the protocol
  • Subjects are able to understand and sign the informed consent
  • Subjects with temperature <=37.0°C on axillary setting

Exclusion Criteria:

  • Female in pregnancy
  • Subjects who have been vaccinated other rabies vaccines after participating in the phase III clinical study of the vaccine (excluding those who participated in the 8-year booster immunization)
  • Subject who has serious adverse reaction history after vaccination such as allergies, hives, difficulty in breathing, angioedema or abdominal pain or allergic to any ingredient of the this rabies vaccine, including excipient
  • Any acute disease, serious chronic disease, fever,and chronic disease at acute stage
  • Subject with autoimmune diseases or immunodeficiency
  • Subject with asthma, unstable over the past two years requiring emergency treatment, hospitalization, intubation, oral or intravenous corticosteroids
  • Subject with diabetes (Type I or II) excluding gestational diabetes
  • Subject with thyroidectomy history, or require treatment in the past 12 months due to thyroid disease
  • Subject with coagulation abnormalities diagnosed by doctors (such as clotting factor deficiency, coagulation disorders, platelet disorder) or obvious bruises or blood clotting disorder
  • Subject with cancer, or has been treated in active cancer period or not clearly cured, or may recur during the study period
  • Subject with uncontrolled epilepsy or other progressive neurological disease
  • Asplenia, functional asplenia, without a spleen or removal of the spleen caused by any situation
  • Any prior administration of immunodepressant, cytotoxic treatment or inhaled corticosteroids in last 6 months, excluding those corticosteroid spray therapy for allergic rhinitis, topical corticosteroid treatment for acute non-concurrent dermatitis)
  • Ongoing anti-tuberculosis prevention or treatment
  • Subject who cannot comply with the trial requirements, or with mental illness/dual-stage affective psychosis in the past or at present
  • Any medical, psychological, social or other condition judged by investigator, that may interfere subject's compliance with the protocol or signature on informed consent
  • Untolerable adverse reactions occurred after booster dose injection within 10 years later;
  • Any condition that in the opinion of the investigators may be not suitable for continued participation after booster dose injection within 10 years later

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT03774628


Locations
Layout table for location information
China, Jiangsu
Lianshui Xinyi Center for Disease Control and Prevention
Huai'an, Jiangsu, China, 223400
Sponsors and Collaborators
Jiangsu Province Centers for Disease Control and Prevention

Layout table for additonal information
Responsible Party: Jiangsu Province Centers for Disease Control and Prevention
ClinicalTrials.gov Identifier: NCT03774628     History of Changes
Other Study ID Numbers: JSVCT061
First Posted: December 13, 2018    Key Record Dates
Last Update Posted: December 13, 2018
Last Verified: December 2018

Layout table for additional information
Studies a U.S. FDA-regulated Drug Product: No
Studies a U.S. FDA-regulated Device Product: No

Additional relevant MeSH terms:
Layout table for MeSH terms
Rabies
Rhabdoviridae Infections
Mononegavirales Infections
RNA Virus Infections
Virus Diseases
Vaccines
Immunologic Factors
Physiological Effects of Drugs